The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
MONEY MOVES
Maven Broke the Employer Wall. But Look Closely at What Came Through
Maven spent ten years building the most credentialed women’s health platform in the employer market, 2,300+ employers, 28 million covered lives. This week, it opened directly to consumers. No employer required.
The gap it’s targeting is real. 37% of women on GLP-1 or hormone medications receive little to no follow-up care. Only 1 in 5 say their hormonal health is ever considered alongside their reproductive health. For women with PCOS, perimenopause, or fertility considerations, Maven’s approach is a genuine differentiator, most GLP-1 platforms prescribe off a BMI calculator. Maven factors in your reproductive history.
But the price tag tells you who this was built for:
- GLP-1 care: $150/month for oversight and support (medication is separate at $900–$1,300/month without insurance)
- Hormone care: $150 one-time, two virtual visits
- Specialty care: $18–$120 per visit, cash-pay, no insurance
The women most affected by the follow-up gap Maven identified are the least likely to absorb that number.
The broader platform, fertility, maternity, and parenting, isn’t available to consumers yet. That’s expected in 2027.
Nutrition Finally Gets Its Series C Moment and It’s Worth $1.75 Billion
America is metabolically sick. Only 12% of American adults have optimal metabolic health. 70% are overweight or obese. 1 in 3 teenagers has prediabetes. 90% of US healthcare spending goes toward chronic disease, most of it diet-related. Is the market finally correcting?
Nourish just closed a $100M Series C, valuing the company at $1.75 billion, bringing total funding to $215M. The model: every patient paired with a registered dietitian, layered with lab testing, medication management, and AI-driven care coordination. The network covers 10,000+ RDs and 200M+ lives through health plan partnerships.
Unlike most telehealth players, Nourish built its business on insurance integration from the start — in-network with UnitedHealthcare, Aetna, Blue Cross Blue Shield, Cigna, and Medicare. 94% of patients pay $0 out of pocket. That’s not a marketing line. It’s the access argument that justifies a $1.75B valuation.
GLP-1 medications are the entry point. The winners won’t be the platforms handing out prescriptions; they’ll be the ones building clinical infrastructure around them. The care model wrapped around the GLP-1 takers is where the value and the margin live.
INNOVATION
EvvyAI — Finally, an AI Trained on Women, Built for Women
AI promised to democratize healthcare. For women, it’s democratizing the same biases ingrained in the healthcare system and medical research. 1 in 4 Americans now turn to AI for health advice. With 27 million uninsured and 3.8 million more losing coverage this year, that number is climbing. The AI they’re turning to? Built on male data.
Leading AI models fail on approximately 60% of women’s health questions, trained on decades of medical literature that severely underrepresents female physiology. Women are turning to a tool that was never built for them.
Evvy’s EvvyAI is the first AI health advisor built entirely on female-specific biology: trained on 100,000+ vaginal microbiome tests using shotgun sequencing, identifying and contextualizing over 700 distinct microbes across life stages including fertility and menopause. No other company has this dataset.
Operating through a private conversational interface, EvvyAI translates complex microbiome data into personalized guidance and routes users to Evvy’s human clinical team when the question requires it. All formal medical evaluations, diagnostic validations, and prescription care plans stay with licensed clinicians. The AI knows what it doesn’t know.
An AI trained on women’s bodies should be the baseline for women. In 2026, it’s still the exception.
Endometriosis Research Is Decades Behind. Cyclana Bio Is Closing the Gap.
1 in 10 women has endometriosis. The average time to diagnosis is 7–10 years. There is no cure. Not because a cure is medically impossible, but because the foundational research to develop one doesn’t exist.
Cyclana Bio just enrolled its first patients in PEMP, Predicting Endometriosis Mechanisms and Populations, a 500-patient clinical observational trial approved by the UK Health Research Authority. The study collects biopsies and menstrual fluid to build physiologically relevant 3D models of the disease and identify new drug targets.
PEMP won’t produce a treatment but it will produce something the field has never had: a real biological map of how endometriosis actually works and where drugs can intervene.
LAW & POLICY
North Carolina Just Filed a Bill That Would Make Abortion First-Degree Murder
North Carolina House Bill 1232, filed May 13, proposes a constitutional amendment declaring life begins at fertilization. If passed by the General Assembly and approved by voters in November 2026, a fertilized egg becomes a legal person with full constitutional protection. Abortion at any stage becomes first-degree murder, for the provider, the woman, and potentially anyone who aided or encouraged it, including the father.
But the implications extend well beyond abortion:
- Ectopic pregnancies: A fertilized egg implanted outside the uterus is fatal without intervention. Treating it means terminating a legal person, leaving physicians criminally exposed and women without life-saving care.
- IVF: Standard protocol creates and discards fertilized embryos. Under HB 1232, that becomes legally untenable. Alabama’s 2024 personhood ruling shut down IVF clinics statewide until emergency legislation intervened.
- Miscarriage criminalization: 10–20% of known pregnancies end in miscarriage. If a fertilized egg is a legal person, every miscarriage becomes a potentially investigable death, placing the burden of proof on the woman.
- Father’s rights: If a fertilized egg is a constitutional person, a father gains potential legal standing to seek a court order preventing termination, regardless of the woman’s wishes or circumstances.
- Medical autonomy: A fetus with equal constitutional standing to the mother makes any medical decision that carries fetal risk legally contestable by a third party.
- Guardian ad litem: Courts could appoint a legal representative for the fertilized egg, giving a third party standing to intervene in decisions a woman and her doctor make together.
- Interstate travel: If abortion is murder in North Carolina, could traveling out of state to obtain one constitute conspiracy to commit murder?
- Substance use: Women who use substances, including some prescription medications, during pregnancy could face criminal charges if a pregnancy ends badly.
The bill is in committee. No vote yet. It heads to North Carolina voters in November 2026 if it clears the General Assembly. Its own co-sponsor Rep. Ben Moss has already walked away.
Pfizer Is Facing Nearly 3,800 Women Over a Birth Control Shot Linked to Brain Tumors. A Make-or-Break Ruling Is Coming.
Depo-Provera, the injectable contraceptive used by nearly 1 in 4 American women between 2015 and 2010, is at the center of one of the largest active women’s health litigations in the US. Nearly 3,800 plaintiffs allege Pfizer knew the drug caused meningioma brain tumors and failed to warn them. New cases are filing at 650 per month.
The science: a JAMA Neurology study of 10 million women across 68 health systems found long-term users had a 2.43x higher risk of meningioma. A separate BMJ study put the risk at 5.55x. No other contraceptive studied showed comparable risk. The FDA added a meningioma warning to the US label in December 2025, decades after the same warning appeared in the EU, UK, and Canada.
The litigation is approaching an all-or-nothing moment. Per Pretrial Order 30, Judge M. Casey Rodgers has ruled that her decisions on Pfizer’s two key defenses, federal preemption and expert causation, will apply to every case in the MDL simultaneously. If Pfizer wins on preemption, all cases are dismissed at once. If it loses, every case moves forward toward the first bellwether trial on December 7, 2026. The preemption motion is fully briefed and under review. Judge Rodgers can issue her ruling at any time — and when she does, it decides the fate of every case at once.
Pfizer’s defense: the FDA rejected its request to update the label, so it can’t be held liable. The FDA’s own December 2025 decision to add a meningioma warning undermines that argument directly, if the FDA was willing to approve the warning, the claim that it was impossible doesn’t hold. Plaintiffs add that Pfizer could have updated the label unilaterally using the FDA’s “Changes Being Effected” process and chose not to.
ON THE FEED
The Soft Girl Era Had a Good Run. It’s Over.
Girlboss burned women out. Soft girl made passivity an aesthetic. Neither was actually the answer.
Women who genuinely like working hard, building things, and choosing effort are done apologizing for it. The aesthetic pendulum didn’t swing back to hustle culture, it landed somewhere sharper.
Friction-maxxing is the pushback a decade of convenience culture had coming. The premise: effort is the price of leveling up: personally, professionally, financially. Convenience culture sold women a shortcut. There isn’t one.
But like every trend before it, friction-maxxing risks becoming a two-week challenge. Women canceling their cleaning service, hand-writing their schedules, swapping Uber Eats for farmers markets, and burning out in a different direction. The problem was never convenience. It was unconsidered convenience.
The real move isn’t maximum friction. It’s strategic convenience. Grocery delivery that buys back two hours on a Wednesday. A cleaning service that removes a recurring source of stress. Those aren’t shortcuts, they’re decisions that create space for the effort that actually matters.
Friction-maxxing is asking the right question: where has convenience made you passive in ways you didn’t choose? The answer isn’t to reject it wholesale. It’s to audit it.
Ozempic Didn’t Bring Back the Thin Ideal. It Pharmaceuticalized It.
For a decade, the culture told women that thinness wasn’t the only standard. Then the pendulum swung back so hard it flew off the wall.
This week, the feed made it impossible to look away. Demi Moore at Cannes, photographed in Gucci, sparked a global reaction. “Skeletal.” “Like a skeleton.” “Very unhealthy.” Kelly Osbourne at the Louis Vuitton Resort 2027 show drew the same. “Pencil legs.” “Zero muscle tone.” “Walking corpse.” Her mother Sharon, who dropped under 100 pounds on Ozempic and has been unable to regain weight since stopping, is the cautionary tale nobody wanted to become.
This is what going too far looks like: not weight loss. Muscle wasting. Hollowed cheeks. The gaunt, aged appearance doctors now call “Ozempic face”, rapid fat loss without muscle preservation. The pattern across 2026 red carpets is too common and consistent.
Ashley Graham called GLP-1s “a smack in the face.” Jameela Jamil called the current aesthetic “scarily thin.” When these bodies go viral and land in the feeds of teenage girls, the standard doesn’t stay in Hollywood. In fact, it’s already spread too far and wide to women across the nation.